SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 28.68-2.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jackie who wrote (7449)10/8/1998 8:04:00 AM
From: Robert K.  Read Replies (5) of 17367
 
This might help the discussion along........>>>>>>>>>>>>>>>>>>>>>
>>>>
>5731415 : Lipopolysaccharide binding protein derivatives
------------------------------------------------------------------------
10 CLAIMS

What is claimed is:
    1. A lipopolysaccharide binding protein (LBP) derivative hybrid protein consisting of an LBP amino acid sequence selected from within the amino-terminal half of LBP wherein at least a portion of the LBP sequences SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22 is respectively replaced with at least a portion effective for endotoxin binding of the bactericidal/permeability-increasing (BPI) sequences SEQ ID NO:17, SEQ ID NO:18, or SEQ ID NO:19.
    2. The hybrid protein according to claim 1 which is LBP(1-87)/BPI(88-100)/LBP(101-197) (SEQ ID NO:51).
    3. The hybrid protein according to claim 1 which is LBP(1-146)/BPI(148-161)/LBP(160-197) (SEQ ID NO:52).
    4. The hybrid protein according to claim 1 which is LBP(1-87)/BPI(88-100)/LBP(101-146)/BPI(148-161)/LBP(160-197) (SEQ ID NO:53).
    5. A DNA sequence consisting of a DNA encoding an LBP derivative hybrid protein according to claim 1.
    6. A DNA vector comprising the DNA sequence according to claim 5.
    7. A host cell stably transformed or transfected with a DNA sequence according to claim 5 in a manner allowing expression in the host cell of the protein encoded thereby.
    8. A pharmaceutical composition comprising an LBP derivative hybrid protein according to claim 1 and a pharmaceutically acceptable diluent, adjuvant or carrier.
    9. A method of treating a gram-negative bacterial infection comprising administering an LBP derivative hybrid protein of claim 1.
    10. The method of claim 9 wherein the LBP derivative hybrid protein is administered at a dosage of from about 0.1 mg/kg to about 100 mg/kg of body weight.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News